CEL-SCI (NYSE:CVM) (NYSE:CVM) is a clinical-stage biotechnology company headquartered in Vienna, Virginia, dedicated to the development of novel immunotherapy products for cancer and infectious diseases. Founded in 1983, the company has built a research and development platform centered on stimulating the body’s own immune system to combat malignancies. With proprietary technologies in active clinical evaluation, CEL-SCI aims to address significant unmet medical needs through targeted immunomodulation.
The company’s lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is designed as a pre-surgical adjuvant for advanced head and neck cancer. Multikine works by activating key immune cell populations at the tumor site, and its pivotal Phase III trial is assessing efficacy on overall survival and disease progression. Alongside Multikine, CEL-SCI is advancing earlier-stage programs that leverage its immunotherapy platforms in both oncology and infectious disease settings.
Beyond Multikine, CEL-SCI’s pipeline includes the LEAPS (Ligand Epitope Antigen Presentation System) technology for autoimmune and infectious indications, and the VaxHit™ platform for rapid vaccine screening and development. These platforms reflect the company’s broader strategy of creating versatile immune-based treatments. CEL-SCI maintains research collaborations and proprietary manufacturing capabilities, with laboratory facilities in the United States and partnerships for clinical supply in Europe and Latin America.
Under the leadership of President and CEO Geert Kersten, CEL-SCI’s executive team and scientific advisory board comprise experts in oncology, immunology and clinical development. The company conducts multi-regional clinical programs and regulatory filings to bring its therapies to patients globally. With a focus on rigorous clinical design and strategic collaborations, CEL-SCI seeks to establish new standards in immunotherapy for challenging diseases.
